MODERN ASPECTS OF PRINCIPLES FOR IMPROVING THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

Authors

  • Doniyor Saidakhmad o'g'li Yo'ldoshev Student of the Faculty of Medicine at Tashkent State Medical University Author

Keywords:

Keywords. Prevention of cardiovascular disease; American Society for Preventive Cardiology; Women's health, cardiovascular risk factors, hypertension, lipoprotein (a)

Abstract

Abstract. The 2025 American Society for Preventive Cardiology meeting showcased new approaches to preventing cardiovascular disease, including risk models based on established risk factors, new biomarkers, innovative treatments, and advancements in digital health. Important topics of discussion included inflammation and lipoprotein(a) [Lp(a)] as causal risk factors, their clinical management, and preparedness for targeted therapies; the best systolic blood pressure targets based on recent RCTs; and the continuing controversy over apolipoprotein B versus low-density lipoprotein cholesterol (LDL-C) as the main lipid target. Digital health advancements focused on wearables' expanding importance, health equity in technology, and prevention using artificial intelligence. Sessions emphasized the importance of imaging in risk assessment, tracking treatment response, and improving preventative tactics, particularly for young adults. Women-specific risk factors and the shortcomings of existing risk prediction algorithms were highlighted in sessions on women's cardiovascular health. The use of polygenic risk scores in young individuals and methods for universal screening with LDL-C, hsCRP, and Lp(a) were also discussed. With a focus on stage-based risk assessment, early detection of subclinical disease, and focused therapies to avoid progression to symptomatic heart failure, heart failure prevention was identified as a crucial frontier. Renal denervation's safety, effectiveness, and longevity as an adjuvant treatment for resistant hypertension were confirmed by updates. When taken as a whole, these highlights show how quickly preventive cardiology is developing, incorporating new treatments, digital tools, and precise risk assessment into standard therapy.

References

1.Filtz A, Shapiro MD, Whelton PK, Navar AM, Rodriguez F, Martin SS, Gulati M, Blankstein R, Ridker PM, Bhatt DL, Yancy CW, Maron DJ, Slipczuk L. Evolving strategies in cardiovascular disease prevention: 2025 American society for preventive cardiology highlights. Am J Prev Cardiol. 2025 Nov 22;24:101357. doi: 10.1016/j.ajpc.2025.101357.

2.Razavi A.C., Bhatia H.S., Blumenthal R.S., Shapiro M.D., Why Mehta A. How and in whom should we measure levels of lipoprotein(a): a review of the latest evidence and clinical implications. Diabetes Obes Metab. 2025;27(S8):34–46. doi: 10.1111/dom.16469.

3.Reyes-Soffer G., Ginsberg H.N., Berglund L., et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arter Thromb Vasc Biol. 2022;42(1):e48–e60. doi: 10.1161/ATV.0000000000000147.

4.Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455.

5.Pearson G.J., Thanassoulis G., Anderson T.J., et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of Cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–1150. doi: 10.1016/j.cjca.2021.03.016.

6.Koschinsky M.L., Bajaj A., Boffa M.B., et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308–e319. doi: 10.1016/j.jacl.2024.03.001.

7.Awad K., Mahmoud A.K., Abbas M.T., et al. Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population. Eur J Prev Cardiol. 2025;32(9):716–721. doi: 10.1093/eurjpc/zwae341.

8.Marcovina S.M., Shapiro M.D. Measurement of lipoprotein(a): a once in a lifetime opportunity. J Am Coll Cardiol. 2022;79(7):629–631. doi: 10.1016/j.jacc.2021.11.053.

9.Szarek M., Reijnders E., Jukema J.W., et al. Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of 3 tests. Circulation. 2024;149(3):192–203. doi: 10.1161/CIRCULATIONAHA.123.066398.

10.Shapiro M.D., Haddad T.M., Weintraub H.S., et al. Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: a subanalysis from the Lp(a)HERITAGE study. J Clin Lipidol. 2025;19(1):28–38. doi: 10.1016/j.jacl.2024.11.007.

11.Patel A.P., Wang (汪敏先) M., Pirruccello J.P., et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arter Thromb Vasc Biol. 2021;41(1):465–474. doi: 10.1161/ATVBAHA.120.315291.

12.Morze J., Melloni G.E.M., Wittenbecher C., et al. ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. Eur Heart J. 2025;46(27):2691–2701. doi: 10.1093/eurheartj/ehaf207.

13.Naghavi M., Reeves A.P., Atlas K., et al. Artificial intelligence applied to coronary artery calcium scans (AI-CAC) significantly improves cardiovascular events prediction. NPJ Digit Med. 2024;7(1):309. doi: 10.1038/s41746-024-01308-0.

14.Khan S.S., Coresh J., Pencina M.J., et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148(24):1982–2004. doi: 10.1161/CIR.0000000000001191.

15.Lincoff A.M., Brown-Frandsen K., Colhoun H.M., et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. doi: 10.1056/NEJMoa2307563.

16.Dores H, Ferreira Santos J, Gil V, Gonçalves PdA. Cardiovascular Prevention: Current Gaps and Future Directions. Diagnostics. 2026; 16(1):16. https://doi.org/10.3390/diagnostics16010016

17.Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P.; et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J. Am. Coll. Cardiol. 2020, 76, 2982–3021.

18.Leong, D.P.; Yusuf, R.; Iqbal, R.; Avezum, Á.; Yusufali, A.; Rosengren, A.; Chifamba, J.; Lanas, F.; Diaz, M.L.; Miranda, J.J.; et al. The burden of cardiovascular events according to cardiovascular risk profile in adults from high-income, middle-income, and low-income countries (PURE): A cohort study. Lancet Glob. Health 2025, 13, e1406–e1414.

19.Bolnick, H.J.; Bui, A.L.; Bulchis, A.; Chen, C.; Chapin, A.; Lomsadze, L.; Mokdad, A.H.; Millard, F.; Dieleman, J.L. Health-care spending attributable to modifiable risk factors in the USA: An economic attribution analysis. Lancet Public Health 2020, 5, e525–e535.

20.Mendis, S.; Graham, I.; Narula, J. Addressing the Global Burden of Cardiovascular Diseases; Need for Scalable and Sustainable Frameworks. Glob. Heart 2022, 17, 48. GBD 2023 Cardiovascular Disease Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. J. Am. Coll. Cardiol. 2025, S0735-1097(25)07428-5.

21.Javaid, A.; Zghyer, F.; Kim, C.; Spaulding, E.M.; Isakadze, N.; Ding, J.; Kargillis, D.; Gao, Y.; Rahman, F.; Brown, D.E.; et al. Medicine 2032: The future of cardiovascular disease prevention with machine learning and digital health technology. Am. J. Prev. Cardiol. 2022, 12, 100379.

22.Biondi-Zoccai, G.; Mahajan, A.; Powell, D.; Peruzzi, M.; Carnevale, R.; Frati, G. Advancing cardiovascular care through actionable AI innovation. npj Digit. Med. 2025, 8, 249.

23.Giugni, F.R.; Berry, J.D.; Khera, A.; Shah, A.M.; de Lemos, J.A. Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far? Circulation 2024, 150, 1720–1731.

24.Mach, F.; Koskinas, K.C.; Roeters van Lennep, J.E.; Tokgözoğlu, L.; Badimon, L.; Baigent, C.; Benn, M.; Binder, C.J.; Catapano, A.L.; De Backer, G.G.; et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur. Heart J. 2025, 46, 4359–4378.

25.Chong, B.; Jayabaskaran, J.; Jauhari, S.M.; Chan, S.P.; Goh, R.; Kueh, M.T.W.; Li, H.; Chin, Y.H.; Kong, G.; Anand, V.V.; et al. Global burden of cardiovascular diseases: Projections from 2025 to 2050. Eur. J. Prev. Cardiol. 2025, 32, 1001–1015.

26.Ray, K.K.; Haq, I.; Bilitou, A.; Manu, M.C.; Burden, A.; Aguiar, C.; Arca, M.; Connolly, D.L.; Eriksson, M.; Ferrières, J.; et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg. Health Eur. 2023, 29, 100624.

27.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021, 398, 957–980.

28.Dai, X.; Gakidou, E.; Lopez, A.D. Evolution of the global smoking epidemic over the past half century: Strengthening the evidence base for policy action. Tob. Control 2022, 31, 129–137.

29.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: A pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 2024, 404, 2077–2093.

Downloads

Published

2026-06-09